Please assess the completion status of the following clinical trial:

Trial Title: Tumor Perfusion and Hypoxia Assessed by DCE-MRI and 18F-FMISO PET as Biomarkers of Treatment Response in Cervical Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy-documented, newly-diagnosed primary cervical cancer of all histopathology types.~* Clinically visible gross lesion (International Federation of Gynecology and Obstetrics (FIGO) stage IB1 and above).~* Treatment (chemoradiation), DCE-MRI and 18F-FMISO PET studies will be at MSKCC.~* Patients must be an adult female 18 years of age or older.~Exclusion Criteria:~* Patients who because of general medical or psychiatric condition, or physiologic status cannot give an informed consent.~* Patients who received prior radiation treatment to pelvis.~* Patients with contraindications to DCE-MRI (non-compatible cardiac pacemakers or intracranial vascular clips, allergy to Gadolinium, end-stage renal disease) and/or 18F-FMISO PET.~* Patients who do not fulfill the screening criteria for safe DCE-MRI or 18F-FMISO PET as per the Department of Radiology guidelines.~* Pregnant patients; and or patients who are breast-feeding their babies.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DCE-MRI and 18F-FMISO PET (Type: EXPERIMENTAL): Each patient will undergo three DCE-MRI (dynamic contrast-enhanced MRI) studies: a baseline DCE-MRI within two weeks before chemoradiation; a second DCE-MRI after the second week of treatment (within a week); and a third DCE-MRI three months after treatment. As a pilot study in 10 patients, we will perform 18F-FMISO PET/CT on the same day of a baseline DCE-MRI before chemoradiation. Treatment decisions will not be based on DCE-MRI and 18F-FMISO PET/CT studies.

Based on this trial design, predict the completion outcome and termination type (if applicable).